Cover ImageSALE
市場調查報告書

心絞痛治療藥的全球市場:2017年∼2021年

Global Angina Pectoris Drugs Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 551748
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
心絞痛治療藥的全球市場:2017年∼2021年 Global Angina Pectoris Drugs Market 2017-2021
出版日期: 2017年08月24日 內容資訊: 英文 82 Pages
簡介

全球心絞痛治療藥市場預測在2017年到2021年間,將以4.05%的年複合成長率 (CAGR) 擴大。

本報告依藥物類別及地區別提供全球心絞痛治療藥市場現狀分析與今後預測,再加上市場成長因素與課題,主要趨勢,主要企業簡介等資訊。

第1章 摘要整理

第2章 本報告的調查範圍

第3章 調查手法

第4章 簡介

  • 市場概要

第5章 市場形勢

  • 市場概要
  • 波特的五力分析

第6章 開發平台形勢

第7章 各類藥物的市場分類

  • 乙型阻斷劑
  • 鈣離子通道阻斷劑
  • 硝酸藥
  • 血管收縮素轉化酵素抑制劑
  • 其他

第8章 地理區分

  • 各地區市場
  • 南北美洲
  • 歐洲·中東·非洲地區
  • 亞太地區

第9章 決策架構

第10章 市場成長因素與課題

  • 市場成長因素
  • 市場課題

第11章 市場趨勢

第12章 業者情勢

  • 競爭情形

第13章 主要供應商分析

  • AstraZeneca
  • Gilead
  • Novartis
  • Pfizer
  • 其他卓越供應商

第14章 附錄

  • 簡稱清單
目錄
Product Code: IRTNTR14638

About Angina Pectoris Drugs

Angina is a type of chest pain or discomfort caused due to a coronary heart disease, specifically due to reduced blood flow to the heart. For angina pectoris drugs market, beta blockers remain the most preferred line of treatment. However, the treatment market witnesses a strong presence of other drug classes such as calcium channel blockers. Though the market is fragmented, large players such as AstraZeneca, Gilead, Novartis, and Pfizer hold significant positions.

Technavio's analysts forecast the global angina pectoris drugs market to grow at a CAGR of 4.05% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global angina pectoris drugs market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Angina Pectoris Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Gilead
  • Novartis
  • Pfizer

Other Prominent Vendors

  • ABayer HealthCare
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Merck
  • Mylan
  • Teva Pharmaceutical

Market driver

  • Increase in chronic diseases
  • For a full, detailed list, view our report

Market challenge

  • Highly genericized market
  • For a full, detailed list, view our report

Market trend

  • Launch of novel pharmacologic agents
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Market landscape

  • Market overview
  • Five forces analysis

PART 06: Pipeline landscape

PART 07: Market segmentation by drug class

  • Beta blockers
  • Calcium channel blockers
  • Nitrates
  • Angiotensin-converting enzyme inhibitors
  • Others

PART 08: Geographical segmentation

  • Market overview based on geography
  • Angina pectoris drugs market in Americas
  • Angina pectoris drugs market in EMEA
  • Angina pectoris market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges

  • Market drivers
  • Market challenges

PART 11: Market trends

  • Launch of novel pharmacologic agents
  • Genomic medicines
  • Growing strategic alliances

PART 12: Vendor landscape

  • Competitive landscape

PART 13: Key vendor analysis

  • AstraZeneca
  • Gilead
  • Novartis
  • Pfizer
  • Other prominent vendors

PART 14: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Major angina types
  • Exhibit 02: Causes, symptoms, and risk factors for angina pectoris
  • Exhibit 03: Diagnosis and treatment of angina pectoris
  • Exhibit 04: Global angina pectoris drugs market snapshot
  • Exhibit 05: Global angina pectoris drugs market 2016-2021 ($ millions)
  • Exhibit 06: Opportunity analysis of the global angina pectoris drugs market
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Pipeline molecules by key vendors 2016
  • Exhibit 09: Key clinical trials
  • Exhibit 10: Segmentation of global angina pectoris market by drug class
  • Exhibit 11: Segmentation of global angina pectoris market by drug class 2016 and 2021
  • Exhibit 12: Global angina pectoris drugs market by beta blockers 2016-2021 ($ millions)
  • Exhibit 13: Common beta blockers used in cardiovascular disorders
  • Exhibit 14: Adverse effects of beta-blockers
  • Exhibit 15: Global angina pectoris drugs market by calcium channel blockers 2016-2021 ($ millions)
  • Exhibit 16: Common calcium channel blockers used for angina pectoris
  • Exhibit 17: Antianginal effects of calcium channel blockers
  • Exhibit 18: Adverse effects of calcium channel blockers
  • Exhibit 19: Nitrates for treatment of angina pectoris
  • Exhibit 20: Global angina pectoris drugs market by nitrates 2016-2021 ($ millions)
  • Exhibit 21: Effect of nitrates on cardiovascular system
  • Exhibit 22: Nitroglycerine used for the treatment and prevention of angina pectoris
  • Exhibit 23: Global angina pectoris drugs market by angiotensin-converting enzyme inhibitors 2016-2021 ($ millions)
  • Exhibit 24: Adverse effects of angiotensin-converting enzyme inhibitors
  • Exhibit 25: Other drug classes used for the treatment of angina pectoris
  • Exhibit 26: Global angina pectoris drugs market by others 2016-2021 ($ millions)
  • Exhibit 27: Antiplatelet agents used for treatment of angina pectoris
  • Exhibit 28: Anti-ischemic agent used in treatment of angina pectoris
  • Exhibit 29: Global angina pectoris drugs market share by geography 2016 and 2021
  • Exhibit 30: Global angina pectoris drugs market by geography 2016-2021 ($ millions)
  • Exhibit 31: Market scenario in Americas
  • Exhibit 32: Angina pectoris drugs market in Americas 2016-2021 ($ millions)
  • Exhibit 33: Market scenario in EMEA
  • Exhibit 34: Angina pectoris drugs market in EMEA 2016-2021 ($ millions)
  • Exhibit 35: Market scenario in APAC
  • Exhibit 36: Angina pectoris drugs market in APAC 2016-2021 ($ millions)
  • Exhibit 37: Top Asian countries in terms of population with diabetes
  • Exhibit 38: World population by age group: 2015-2050 (million)
  • Exhibit 39: Percentage of population aged 60 and above by region 2015-2050
  • Exhibit 40: Major complications of diabetes
  • Exhibit 41: Global obesity facts 2014
  • Exhibit 42: Competitive structure analysis of global angina pectoris drugs market
  • Exhibit 43: AstraZeneca: Key highlights
  • Exhibit 44: AstraZeneca: Strength assessment
  • Exhibit 45: AstraZeneca: Strategy assessment
  • Exhibit 46: AstraZeneca: Opportunity assessment
  • Exhibit 47: Gilead: Key highlights
  • Exhibit 48: Gilead: Strength assessment
  • Exhibit 49: Gilead: Strategy assessment
  • Exhibit 50: Gilead: Opportunity assessment
  • Exhibit 51: Novartis: Key highlights
  • Exhibit 52: Novartis: Strength assessment
  • Exhibit 53: Novartis: Strategy assessment
  • Exhibit 54: Novartis: Opportunity assessment
  • Exhibit 55: Pfizer: Key highlights
  • Exhibit 56: Pfizer: Strength assessment
  • Exhibit 57: Pfizer: Strategy assessment
  • Exhibit 58: Pfizer: Opportunity assessment
Back to Top